drugset / Trial / NCT02537054

Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)

NCT02537054

Phase 2 Completed 15 enrolled University Hospital, Bonn
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Aflibercept (Eylea) is effective in the treatment of choroidal neovascularization and fibrovascular proliferation in patients with pseudoxanthoma elasticum (PXE) in terms of preservation or improvement of visual acuity.

Timeline

Start
2015-09
Primary completion
2018-07-02
Completion
2018-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal